The Company has strategic partnership with GE (China), Sinopharm Group Co, China Life Insurance, and Beijing Persee General. It has strong historic financial returns and a strong management team with deep knowledge and experience. The Company has multiple avenues for growth, including expansion current hospital capacities and potential acquisitions. It is planning the first Chinese hospital listing in overseas.
The Chinese Private Healthcare Market:
- Chinese Private Healthcare sector has become a major attraction of international investment target since 2007
- Large and unmet market demand in industry exhibiting strong growth.
- The hospital industry account for majority of the healthcare industry growth.
- New policies boosting health care sector in 2013, including equal pricing, expenditure, tax, recruitment polices between private owned and government owned hospitals.
Company Finance
- Strong 2010 to 2012 annual top and bottom line growth:
- Sales CAGR of 27.88%
- Net income CAGR of 18.99%
- U.S. listing platform to fuel both organic growth and growth through acquisition: Current organic growth limited by operational capacity. Additional capital will fuel growth.
- Potential acquisitions utilizing stock as currency to acquire similar hospitals throughout China.
Financial Highlights:
Year Revenues Net Income
2015 $19.7mn $6.25mn
2014 $11mn $3.55mn
2013 $4.45mn $1.63mn
2012 $3.48mn $1.15mn
2011 $2.66mn $0.99mn
2010 $2.05mn $0.81mn
2009 $1.66mn $0.68mn
- IPO Proceeds: $4.58million
- Number of shares to be issued: 8mn
Operational Expansion:
- Space in sqm: From 3,200 to 25,000
- Beds: From 150 to 500
- Medical Staff: From 157 to 314
- Admin Staff: From 35 to 70